Dismantling the Necroptotic Engine: An Oral Theranostic Nanosponge for Ulcerative Colitis

Area of Science:

• Gastroenterology and Nanomedicine
• Biomaterials and Drug Delivery

Background:

• Ulcerative Colitis (UC) treatments face challenges with specificity and side effects.
• Excessive intestinal epithelial cell (IEC) necroptosis drives UC pathology and gut barrier dysfunction.

Purpose of the Study:

• To develop an intelligent oral theranostic nanoplatform, CurN@I, for Ulcerative Colitis.
• To target and dismantle the necroptosis-inflammation axis in the gut.

Main Methods:

• Designed CurN@I with a barium sulfate core for CT imaging, a pH-responsive silk nanosponge, and co-loaded necroptosis inhibitor (Necrostatin-1s) and antioxidant (demethoxycurcumin).
• Utilized pH-responsive swelling and negative surface charge for localized drug release and mucosal adhesion.
• Evaluated efficacy in murine UC models.

Main Results:

• Oral CurN@I demonstrated superior performance compared to first-line clinical drugs in murine UC models.
• The nanoplatform inhibited IEC necroptosis, reduced oxidative stress, and promoted gut barrier regeneration.
• CurN@I treatment reshaped the gut microbiome and restored intestinal homeostasis.

Conclusions:

• CurN@I presents a non-invasive, targeted oral theranostic strategy for Ulcerative Colitis.
• The integrated diagnostic and multi-faceted therapeutic approach shows significant potential for clinical translation.
• This nanoplatform effectively addresses UC by targeting key pathological mechanisms.